While the Buy rating suggests confidence in Pfizer's fundamentals and potential for growth, the reduction in the price target may reflect a reassessment of near-term growth prospects or market conditions. This could lead to mixed reactions in the market, with some investors seeing the lowered target as a sign of caution, while others may focus on the maintained Buy rating as a positive signal.